Next report date
Report period
Q1 2024
EPS estimate
0.91EUR
Revenue estimate
53.48 MEUR
33.30 MEUR
295.83 MEUR
11.43 M
About Eagle Pharmaceuticals, Inc.
Sector
CEO
Michael Graves
Headquarters
Woodcliff Lake
Website
Employees (FY)
135
Founded
2007
FIGI
BBG00645T0X2
Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. Its products include RYANODEX, BENDEKA and BELRAPZO. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.
EGRX ShortNice rounded top in EGRX... Liking a short here on this one as well. If it breaks through that support around $35 we could see a nice plunge.
$EGRX on Be prepared for possible GrowthAs Eagle Pharma Win Patent Decision for Bendeka, Court issued a favorable patent decision for Bendeka bendamustine hydrochloride injection, or bendamustine HCl , a liquid, low-volume and short-time 10-minute infusion formulation of bendamustine hydrochloride. So with that $EGRX shares rose 23% to $6
Eagle Pharmaceuticals on verge of breakout. Price entry $60 - target price $ 66 stop loss $58
Despite the stock been above the average analysts target we remain bullish om the setup technically, there is also the chance of upgrades to follow.
P/E ratio 20.65
Short interest 14.62 % Quite High, but normal in the Pharma sector.
EAGLE PHARMA ready to break out. ===============
SHORT TERM PRICE TARGET $68 +15% UPSIDE
===============
Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban, ryanodex, docetaxel injection, non-alcohol formulation and bendeka. The company was founded by Scott L. Tarriff on
EGRX flag break, looking for a follow through higher This just recently broke out of a flag pattern, so I'm going long tomorrow watching if it can keep going higher.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange EAGLE PHARMACEUTI.DL-,001 stocks are traded under the ticker 1E6.
EAGLE PHARMACEUTI.DL-,001 is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
1E6 earnings for the last quarter are 1.08 EUR per share, whereas the estimation was 0.96 EUR resulting in a 12.38% surprise. The estimated earnings for the next quarter are 1.03 EUR per share. See more details about EAGLE PHARMACEUTI.DL-,001 earnings.
EAGLE PHARMACEUTI.DL-,001 revenue for the last quarter amounts to 59.27 M EUR despite the estimated figure of 54.20 M EUR. In the next quarter revenue is expected to reach 59.41 M EUR.
Yes, you can track EAGLE PHARMACEUTI.DL-,001 financials in yearly and quarterly reports right on TradingView.
No, 1E6 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 1E6 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade EAGLE PHARMACEUTI.DL-,001 stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 28, 2024, the company has 135.00 employees. See our rating of the largest employees — is EAGLE PHARMACEUTI.DL-,001 on this list?